TY - JOUR
T1 - Ovarian cancer, version 3.2012
T2 - Featured updates to the NCCN guidelines
AU - Morgan, Robert J.
AU - Alvarez, Ronald D.
AU - Armstrong, Deborah K.
AU - Burger, Robert A.
AU - Castells, Mariana
AU - Chen, Lee May
AU - Copeland, Larry
AU - Crispens, Marta Ann
AU - Gershenson, David
AU - Gray, Heidi
AU - Hakam, Ardeshir
AU - Havrilesky, Laura J.
AU - Johnston, Carolyn
AU - Lele, Shashikant
AU - Martin, Lainie
AU - Matulonis, Ursula A.
AU - O'Malley, David M.
AU - Penson, Richard T.
AU - Remmenga, Steven W.
AU - Sabbatini, Paul
AU - Santoso, Joseph T.
AU - Schilder, Russell J.
AU - Schink, Julian
AU - Teng, Nelson
AU - Werner, Theresa L.
AU - Hughes, Miranda
AU - Dwyer, Mary A.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2012/11/1
Y1 - 2012/11/1
N2 - These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.
AB - These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.
UR - http://www.scopus.com/inward/record.url?scp=84871415258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871415258&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2012.0140
DO - 10.6004/jnccn.2012.0140
M3 - Review article
C2 - 23138163
AN - SCOPUS:84871415258
SN - 1540-1405
VL - 10
SP - 1339
EP - 1349
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 11
ER -